Press Releases

DVIDS - Georgia

FRANKFORT, Ky. — For U.S. Army Brig. Gen. Joseph Lear, rucking for 12 miles seemed familiar.

GlobeNewswire, Inc.

Chaired by Mo Qatanani, PhD, Clinical & Scientific Advisory Board brings deep expertise in obesity, cardiometabolic disease and drug development Board will guide MitoRx's development strategy for lead asset MTRX31 as it advances towards the clinic...

GlobeNewswire, Inc.

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and cardiovascular diseases,...

GlobeNewswire, Inc.

Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078),...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally...

GlobeNewswire, Inc.

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms.

DVIDS - Georgia

RAMSTEIN AIR BASE, Germany — Landstuhl Regional Medical Center teamed up with the 86th Medical Group and NATO partner forces to co-host the Royal Danish Air Force Flyver Ruck March on Aug. 29. The event drew more than 500 in-person participants...

GlobeNewswire, Inc.

Company announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),...

GlobeNewswire, Inc.

Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure Early biomarker signals are consistent with pathway modulation in the...

GlobeNewswire, Inc.

Press release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company...

GlobeNewswire, Inc.

Company aims to link genetic variants to their biological functions and effects on disease Founding team includes disease genomics expert and Broad Institute Member Melina Claussnitzer, PHD CaMaRa’s business model builds on its founders’ proven...

GlobeNewswire, Inc.

Copenhagen, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The last meal before a big race can be make-or-break for runners.

GlobeNewswire, Inc.

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday,...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for...

GlobeNewswire, Inc.

Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Sept. 04, 2026 (GLOBE NEWSWIRE) -- The state-of-the-art quantum facility will strengthen Europe’s ability to design, manufacture and scale next-generation quantum chips, helping to position the continent as a global leader in...

GlobeNewswire, Inc.

Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no....

GlobeNewswire, Inc.

Dr. Røpcke joins Resalis with extensive experience in clinical drug development as well as expertise in obesity and cardiometabolic therapy areas Torino, Italy, September 2, 2026 – Resalis Therapeutics, a biotechnology company pioneering...